DNLI Q1 2023 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$35M-16.6% YoY

Gross Profit

$35M100.0% margin

Operating Income

-$121M-343.8% margin

Net Income

-$110M-312.4% margin

EPS (Diluted)

$-0.80

QoQ Revenue Growth

+241.7%

Cash Flow

Operating Cash Flow

-$59M

Free Cash Flow

-$62M

Stock-Based Comp.

$28M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$443M

Stockholders' Equity

$967M

Cash & Equivalents

$68M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$35M	$42M	-16.6%
Gross Profit	$35M	$42M	-16.6%
Operating Income	-$121M	-$66M	-81.7%
Net Income	-$110M	-$65M	-68.3%